In one paragraphArticle in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Azam MajidiHormones and Metabolism Team, Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), Lyon, France.ORCID 0000-0003-2815-3060 Sabina RinaldiHormones and Metabolism Team, Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), Lyon, France.ORCID 0000-0002-6846-1204 Carine BiessyHormones and Metabolism Team, Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), Lyon, France.
Beatrice VozarHormones and Metabolism Team, Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), Lyon, France.
Renée Turzanski FortnerDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-1426-8505 Charlotte Le CornetDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-5291-7545 Matthias B SchulzeDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.ORCID 0000-0002-0830-5277 Camilla PanicoDipartimento di Diagnostica per Immagini, Radioterapia Oncologica e Ematologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID 0000-0002-0472-1118 Giovanna MasalaClinical Epidemiology Unit, Institute for Cancer Research Prevention and Clinical Network (ISPRO), Florence, Italy.ORCID 0000-0002-5758-9069 Fulvio RicceriCentre for Biostatistics, Epidemiology, and Public Health (C-BEPH), Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.ORCID 0000-0001-8749-9737 Claudia VenerEpidemiology and Prevention Unit, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Maria-José SánchezRegistro de Cáncer de Granada, Escuela Andaluza de Salud Pública (EASP), Granada, Spain.ORCID 0000-0003-4817-0757 Raúl Zamora-RosUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-6236-6804 Marta Crous-BouUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0003-1493-4288 Sandra M Colorado-YoharDepartment of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.ORCID 0000-0002-6700-0780 Marcela GuevaraInstituto de Salud Pública y Laboral de Navarra, Pamplona, Spain.
Pernilla IsraelssonDepartment of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden.ORCID 0009-0003-8605-8122 Ruth TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-9571-0763 Elio RiboliCancer Epidemiology and Prevention Research Unit, School of Public Health, Imperial College London, London, UK.ORCID 0000-0001-6795-6080 Laure DossusHormones and Metabolism Team, Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), Lyon, France.ORCID 0000-0003-2716-5748 Funding
Biomedical Research CentreCancer Research UK C8221/A29017Cancer Research UK C864/A14136Catalan Institute of Oncology-ICODepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College LondonDutch Ministry of Public Health, Welfare and SportsFederal Ministry of Education and ResearchFrench Ministry for Higher EducationFrench National Cancer Institute INCA_15874French National Research AgencyGerman Cancer Aid, German Cancer Research CenterGerman Institute of Human Nutrition Potsdam-RehbrueckeInstitut Gustave RoussyInstitut National de la Santé et de la Recherche MédicaleInstituto de Salud Carlos IIIInternational Agency for Research on CancerItalian Ministry of HealthItalian Ministry of University and ResearchItaly: Associazione Italiana per la Ricerca sul Cancro-AIRC-ItalyMedical Research Council MC_UU_00006/1Medical Research Council MC-UU_12015/1Medical Research Council MR/N003284/1Medical Research Council MR/Y013662/1Mutuelle Générale de l'Education NationaleNational Institute for Health and Care ResearchNetherlands Cancer RegistryOrganisation for Health Research and DevelopmentRegional Governments of Andalucía, Asturias, Basque Country, MurciaWorld Cancer Research FundWorld Health Organization 001
6 · The paper itselfAbstract
backgroundThyroid-stimulating hormone (TSH) and thyroid hormones (free triiodothyronine [fT3] and free thyroxine [fT4]) may influence cancer outcomes, but evidence for ovarian cancer is limited.
methodsWe conducted a nested case-control study comparing 578 epithelial ovarian cancer (EOC) cases with matched controls within the European Prospective Investigation into Cancer and Nutrition (EPIC). To examine associations between circulating TSH, fT3, and fT4 levels and EOC risk, we estimated risk ratios (RRs) and 95% confidence intervals (CIs) per SD using conditional logistic regression. Among cases, we evaluated all-cause and EOC-specific survival by prediagnostic hormone levels. Hazard ratios (HRs) and 95% confidence intervals were calculated using multivariable Cox regression. We also estimated covariate-adjusted restricted mean survival time (RMST) and survival probabilities at 5 and 10 years.
resultsThyroid hormones were not associated with EOC risk (RR [95% CI] per SD increase: TSH = 0.99 [0.87 to 1.12], fT3 = 1.12 [0.70 to 1.79], and fT4 = 1.08 [0.56 to 2.07]) levels. However, higher TSH levels were associated with better survival (HR [95% CI] per SD: all-cause death = 0.90 [0.82 to 0.99], EOC-specific = 0.88 [0.79 to 0.97]), whereas higher fT4 levels were associated with worse survival (all-cause = 1.10 [1.00 to 1.22], EOC-specific = 1.17 [1.05 to 1.30]), but no association for fT3. RMST and survival probabilities showed similar patterns: for TSH, 10-year RMST and survival increased from 5.3 years and 42.2% in Quartile 1 (Q1) to 6.4 years and 50.7% in Q4. Conversely, for fT4, 10-year RMST declined from 5.6 years (Q1) to 5.1 years Q4, and survival from 46.3% to 37.8%.
conclusionTSH and thyroid hormones might not affect ovarian cancer risk. However, high fT4 and low TSH concentrations may be associated with poorer survival. Further evaluation is suggested in other populations.
Indexed as
Neoplasms, Glandular and EpithelialOvarian NeoplasmsThyroid HormonesThyrotropinThyroxineTriiodothyronineAdultAgedCarcinoma, Ovarian EpithelialCase-Control StudiesEuropeFemaleHumansMiddle AgedProportional Hazards ModelsProspective StudiesThyroid HormonesThyrotropinThyroxineTriiodothyronine
Identifiers
PMID40811636
PMCPMC12597511
What OpenQuestion holds
Textmetadata
Read underepoch 390